drugset / Trial / NCT01090830
Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to establish the safest dose of the investigational medication Belinostat that can be administered with a standard of care chemotherapy regimen of bevacizumab, carboplatin, and paclitaxel. Further study will examine the short and long-term effect (up to 2 years) of this medication on participant's disease status and overall survival.
Timeline
- Start
- 2010-04
- Primary completion
- 2012-02
- Completion
- 2012-02
Outcome
Outcome not reported
Stopped: “Principal Investigator has left institution. IND withdrawn.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 600 mg/kg | — |
| Subject | Belinostat | Small molecule | 800 mg/kg | — |
| Subject | Belinostat | Small molecule | 1000 mg/kg | — |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | — |